HomeGeneticsConditionCongenital afibrinogenemia
Back to Condition
Congenital afibrinogenemia
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Congenital afibrinogenemia

Congenital afibrinogenemia is a rare, inherited bleeding disorder characterized by a complete absence of fibrinogen, a protein essential for blood clotting. This deficiency prevents the formation of stable blood clots, leading to uncontrolled and potentially life-threatening bleeding.

Overview

Congenital afibrinogenemia is a bleeding disorder caused by impairment of the blood clotting process (coagulation). Normally, blood clots protect the body after an injury by sealing off damaged blood vessels and preventing further blood loss. However, in people with congenital afibrinogenemia, blood clots do not form properly, resulting in uncontrolled bleeding.

Symptoms & Clinical Features

The symptoms of congenital afibrinogenemia can range from mild to life-threatening and include:

  • Prolonged bleeding from the umbilical cord stump after birth in newborns
  • Nosebleeds (epistaxis) and bleeding from the gums or tongue, which can occur spontaneously or after minor trauma
  • Bleeding into the spaces between joints (hemarthrosis) or into the muscles (hematoma)
  • Abnormally heavy menstrual bleeding (menorrhagia) in women
  • Difficulty carrying a pregnancy to term, resulting in repeated miscarriages without proper treatment
  • Rarely, fatal bleeding in the brain or other internal organs

Frequency

Congenital afibrinogenemia is a rare condition that occurs in approximately 1 in 1 million newborns.

Causes & Genetics

Congenital afibrinogenemia results from mutations in one of three genes: FGA, FGB, or FGG.

Each of these genes provides instructions for making one subunit of the protein fibrinogen. This protein is critical for coagulation. In response to an injury, fibrinogen is normally converted into fibrin, the main protein in blood clots. Fibrin proteins attach to one another to form a stable network that makes up the clot.

The condition is caused by a complete absence of the fibrinogen protein. Most mutations in the FGA, FGB, and FGG genes introduce a premature stop signal in the instructions for making the protein, resulting in a nonfunctional or entirely absent subunit. If any one subunit is missing, the fibrinogen protein cannot be assembled, preventing the formation of fibrin and blood clots.

Associated Genes

  • FGA
  • FGB
  • FGG

Inheritance Pattern

Congenital afibrinogenemia is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations.

The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene. These carriers typically have about half the normal level of fibrinogen in their blood but do not show signs and symptoms of the condition.

Other Names for This Condition

  • Afibrinogenemia
  • Familial afibrinogenemia

Frequently Asked Questions

Critical bleeding symptoms that require immediate medical attention include severe or prolonged bleeding from any site that doesn't stop with direct pressure, significant head injuries, severe abdominal pain, sudden severe headache, or any signs of internal bleeding such as unusual bruising, swelling, or joint pain. Prolonged bleeding from the umbilical cord stump in newborns is also a key indicator.
The primary treatment involves replacement therapy with fibrinogen concentrate (human plasma-derived) or fresh frozen plasma (FFP) to provide the missing fibrinogen. This can be given on demand to treat active bleeding or as prophylactic (preventive) treatment before surgeries, during pregnancy, or in individuals with frequent bleeding episodes. Antifibrinolytic agents like tranexamic acid may also be used to stabilize clots.
Individuals should avoid activities that carry a high risk of injury. Before any surgery, dental procedure, or invasive medical procedure, it is crucial to inform all healthcare providers about the condition. Prophylactic fibrinogen replacement therapy is typically administered before these procedures to prevent excessive bleeding. Regular dental hygiene is important to prevent gum bleeding, and non-steroidal anti-inflammatory drugs (NSAIDs) should generally be avoided due to their antiplatelet effects.
Women with congenital afibrinogenemia face a high risk of recurrent miscarriages and severe bleeding during pregnancy and childbirth. Close monitoring by a multidisciplinary team (hematologist, obstetrician) is essential. Prophylactic fibrinogen replacement therapy is typically initiated early in pregnancy and continued throughout, especially during delivery, to prevent complications like placental abruption, miscarriage, and postpartum hemorrhage. Careful planning and management are crucial for a successful pregnancy.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab